Performance ResearchResearch OnlyNot For Human Consumption

Cardarine

GW501516 · GW1516 · Endurobol · PPAR-δ agonist

Shifts your muscles to studied for fat metabolism for fuel, dramatic endurance and cholesterol improvements in clinical trials, though development was halted.

MECHANISM OF ACTION

Cardarine is a small molecule (not a peptide) that activates a switch called PPAR-delta, found in muscle cells. This switch controls which fuel source the muscles prefer to burn. When activated, muscles shift strongly towards burning fat rather than sugar, making more fat available as energy and improving stamina. It also triggers the growth of more mitochondria (the energy-producing parts of cells) and raises HDL cholesterol (the "good" kind). Originally developed by GlaxoSmithKline for metabolic syndrome, it reached Phase II clinical trials where it showed remarkable endurance and cholesterol benefits at very low doses. Clinical development was halted for reasons unrelated to its mechanism, but the research data is publicly available and remains of interest to scientists studying metabolism and exercise physiology.

RESEARCH APPLICATIONS

  • Endurance and aerobic capacity research
  • Fatty acid oxidation and body composition
  • HDL elevation and dyslipidaemia models
  • PPAR-δ receptor pharmacology
  • Metabolic syndrome research

RESEARCH HIGHLIGHTS

PPAR-δ Endurance Enhancement

2004

Preclinical gene-expression models expressing constitutively active PPAR-δ ran twice as far as controls - the "marathon mouse" model that first identified GW501516 as an endurance target.

Ref: Wang et al., PLOS Biol

Phase II: HDL +79%, LDL -7%

2007

Phase II metabolic syndrome trial: GW501516 produced dramatic HDL increases and HDL particle size improvement vs. placebo over an 8-week research period.

Ref: Sprecher et al., Arterioscler Thromb Vasc Biol

RESEARCH PROTOCOL NOTES

Available formatsOral capsule/tablet - not injectable
Physical formSupplied lyophilised (freeze-dried powder) unless stated otherwise
ReconstitutionBacteriostatic water; swirl gently, do not shake

Chemical Identity

CAS Number317318-70-0

Storage & Stability

Small molecule, oral formulation. Store at room temperature away from moisture and light. Stable for 12–24 months if sealed.

Regulatory Status

Clinical development discontinued by GSK. Not approved by any regulatory authority. WADA prohibited under S4 (Hormone and Metabolic Modulators). SAHPRA: unscheduled research compound.

Important - read before proceeding

This page is a summary of published scientific literature about a molecule. It is provided for research and educational purposes only. Nothing on this page is medical advice, a diagnosis, a recommendation, a prescription, or a claim that this compound treats, cures, prevents or improves any condition in humans. Research findings described here are observations reported by third-party researchers about the molecule - they are not statements about the product supplied by Bio Intelligence, and they should not be read as an expected outcome.

Compounds supplied are not registered medicines, have not been evaluated by SAHPRA, and are not for human consumption. No dosing, route of administration or usage guidance is provided by Bio Intelligence. If you have a health concern, speak to a registered healthcare practitioner.